Back to top
more

Bruker (BRKR)

(Real Time Quote from BATS)

$63.89 USD

63.89
359,503

-1.99 (-3.02%)

Updated Aug 5, 2024 11:14 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (103 out of 251)

Industry: Instruments - Scientific

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Perion Network (PERI) to Post Q4 Earnings: What to Expect

by Zacks Equity Research

Perion Network's (PERI) fourth-quarter 2022 performance is expected to have benefited from robust advertiser demand for video and CTV as well as SORT solutions.

onsemi's (ON) Q4 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

onsemi's (ON) fourth-quarter 2022 performance reflects strong demand for intelligent and sensing products across automotive and industrial end markets.

Digital Turbine (APPS) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

Digital Turbine's (APPS) fiscal third-quarter earnings are expected to have suffered from macroeconomic challenges including high inflation, which has hurt ad revenue business.

Axcelis (ACLS) to Post Q4 Earnings: Key Factors to Note

by Zacks Equity Research

Axcelis's (ACLS) fourth-quarter performance is likely to have benefited from increased demand for the Purion suite of products.

Skyworks (SWKS) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Skyworks' (SWKS) first-quarter fiscal 2023 results are likely to reflect gains from momentum witnessed in 5G and Wi-Fi 6 solutions amid supply chain constraints.

Microchip (MCHP) Q3 Earnings Top Estimates, Sales Rise Y/Y

by Zacks Equity Research

Microchip's (MCHP) third-quarter fiscal 2023 results reflect continued momentum in the microcontroller business despite the weaker business environment in China.

onsemi (ON) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

onsemi's (ON) fourth-quarter 2022 results are likely to reflect the benefits of the key megatrends such as EVs, energy infrastructure and factory automation.

Cognizant (CTSH) Q4 Earnings Meet Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Cognizant's (CTSH) fourth-quarter 2022 results benefit from strong digital revenues and acquisitions amid a challenging macro environment.

Apple (AAPL) Q1 Earnings Miss Estimates, Revenues Decline Y/Y

by Zacks Equity Research

Apple's (AAPL) first-quarter fiscal 2023 results reflect the supply shortage of iPhone 14 Pro and iPhone 14 Pro Max in November and through December, and a significant forex headwind.

Bruker (BRKR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Bruker (BRKR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Microchip (MCHP) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Microchip's (MCHP) fiscal third-quarter results are likely to reflect robust uptake of microcontrollers, despite supply chain constraints and weak consumer end-market.

Cognizant (CTSH) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Cognizant's (CTSH) fourth-quarter 2022 results are expected to reflect growing domain expertise in its digital business operations despite challenging macroeconomic conditions.

Bruker's (BRKR) New Tie-Up to Expand Its U.S. CRO Business

by Zacks Equity Research

Bruker's (BRKR) latest partnership is expected to expand its CRO business in the United States, benefiting more biopharma and diagnostics companies using unbiased proteomics for decision-making.

Are Options Traders Betting on a Big Move in Bruker (BRKR) Stock?

by Zacks Equity Research

Investors need to pay close attention to Bruker (BRKR) stock based on the movements in the options market lately.

Bruker (BRKR) Q3 Earnings Beat Estimates, '22 Sales View Down

by Zacks Equity Research

Despite ongoing macroeconomic headwinds, Bruker (BRKR) registers strong demand for differentiated high-value scientific instruments and life science solutions.

    Bruker (BRKR) Q3 Earnings and Revenues Surpass Estimates

    by Zacks Equity Research

    Bruker (BRKR) delivered earnings and revenue surprises of 24.53% and 4.14%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

    Analysts Estimate Bruker (BRKR) to Report a Decline in Earnings: What to Look Out for

    by Zacks Equity Research

    Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    BD's (BDX) New Cloud Software Solution to Boost Lab Workflow

    by Zacks Equity Research

    BD's (BDX) latest launch is expected to provide scientists with an integrated ecosystem that enables optimization of panel design, collaboration and analysis.

      Bruker (BRKR) Gains From New Product Bookings Amid Competition

      by Zacks Equity Research

      Bruker's (BRKR) revenue recognition from one gigahertz class NMR system and continued uptake of the timsTOF platform hold promise.

        Here's Why You Should Retain Bruker (BRKR) Stock for Now

        by Zacks Equity Research

        Investors are optimistic about Bruker's (BRKR) segmental results and robust bookings and backlog growth.

        Why Is Bruker (BRKR) Down 11.3% Since Last Earnings Report?

        by Zacks Equity Research

        Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

        Bruker (BRKR) Debuts Innovations for Proteomics & Metabolomics

        by Zacks Equity Research

        Bruker's (BRKR) novel nanoElute 2 and next-generation MetaboScape 2023 release are likely to offer enhanced workflows for proteomics and metabolomics applications.

        BD (BDX) Ties Up With LabCorp to Boost Patient Outcome

        by Zacks Equity Research

        BD's (BDX) latest partnership is expected to provide life-changing treatments for cancer and other diseases, thereby improving patient care.

        Bruker (BRKR) Q2 Earnings Match Estimates, '22 Sales View Down

        by Zacks Equity Research

        Robust performance across the BSI and BEST segments drove Bruker's (BRKR) second-quarter top line.

        Bruker (BRKR) Meets Q2 Earnings Estimates

        by Zacks Equity Research

        Bruker (BRKR) delivered earnings and revenue surprises of 0% and 0.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?